Abstract
Dyslipidemia is a leading risk factor for cardiovascular diseases. Nutraceuticals for the management of dyslipidemia are gaining growing attention. Derived from food sources, they represent a promising adjunctive or alternative therapeutic option in specific clinical contexts, particularly in individuals with mild dyslipidemia or those who fail to achieve lipid targets despite optimal pharmacological treatment. Bergamot-alongside its lipid-lowering effects-has demonstrated multiple additional properties, including anti-inflammatory, antioxidant, and vascular benefits. While lipid effects are supported by several clinical studies, evidence for vascular and inflammatory pathways is based mainly on preclinical studies. This review summarizes the mechanisms of action and available clinical evidence and outlines potential indications for bergamot use in selected patient subgroups.